Novo Nordisk's next-gen obesity drug Cagrisema
Lange explained on a conference call that one reason for the miss was a flexible treatment protocol that allowed patients to ...
The drugmaker’s financial forecasts topped Wall Street’s expectations, reassuring investors after it overestimated demand for ...
Novo Nordisk defended its obesity drug CagriSema despite disappointing trial data. The company remains optimistic about its efficacy compared to Wegovy. Upcoming trials aim to harness its weight-loss ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results